Articles de revue sur le cancer colorectal - Derniè res parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer colorectal (4 février 2008):


Advances in minimally invasive surgery in the treatment of colorectal
cancer.
Brown CJ, Raval MJ.
Expert Rev Anticancer Ther. 2008 Jan;8(1):111-23.

Capecitabine and radiotherapy as neoadjuvant treatment for rectal
cancer.
Ben-Josef E.
Am J Clin Oncol. 2007 Dec;30(6):649-55.

Meta-analysis of hepatic arterial infusion for unresectable liver
metastases from colorectal cancer: the end of an era?
Mocellin S, Pilati P, Lise M, Nitti D.
J Clin Oncol. 2007 Dec 10;25(35):5649-54.

Translational approaches to addressing complex genetic pathways in
colorectal cancer.
Early DS, Fontana L, Davidson NO.
Transl Res. 2008 Jan;151(1):10-6.

Combining targeted therapies to enhance the effectiveness of
chemotherapy in patients with treatment-refractory colorectal cancer.
Eng C.
Clin Colorectal Cancer. 2007 Oct;6 Suppl 2:S53-9.

Factors that influence treatment strategies in advanced colorectal
cancer.
Nesbitt C, Glendinning RJ, Byrne C, Poston GJ.
Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S88-94.

The role of NSAIDs in colon cancer prevention.
Antonakopoulos N, Karamanolis DG.
Hepatogastroenterology. 2007 Sep;54(78):1694-700.

New approaches to assessing and treating early-stage colon and rectal
cancers: cooperative group strategies for assessing optimal approaches
in early-stage disease.
Benson AB 3rd.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s.

Biological therapy and other novel therapies in early-stage disease:
are they appropriate?
Grothey A.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6909s-12s.

Multidisciplinary management of patients with advanced rectal cancer.
Beart RW Jr.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6890s-3s.

Management of early rectal T1 and T2 cancers.
Stamos MJ, Murrell Z.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6885s-9s.

Newer pathologic assessment techniques for colorectal carcinoma.
Turner RR, Li C, Compton CC.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6871s-6s.

New issues in genetic counseling of hereditary colon cancer.
Lynch PM.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6857s-61s.

Integration of the anti-EGFR agent panitumumab into clinical practice
in metastatic colorectal cancer.
Van Cutsem E.
Clin Adv Hematol Oncol. 2007 Aug;5(8):611-3.

Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J, Saura C, Macarulla T, Casado E, Ramos FJ, Tabernero J.
Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S24-34.

Prevention of colorectal cancer in high-risk populations: the
increasing role for endoscopy and chemoprevention in FAP and HNPCC.
Lynch PM.
Digestion. 2007;76(1):68-76.

The clinical efficacy of FOLFIRI and bevacizumab in combination as
first-line therapy of metastatic colorectal cancer.
Grothey E, Chu E.
Clin Colorectal Cancer. 2007 Sep;6(9):621-4.

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for
the potential treatment of cancer.
Tarhini AA, Kirkwood JM.
Curr Opin Mol Ther. 2007 Oct;9(5):505-14.

Blood markers for early detection of colorectal cancer: a systematic
review.
Hundt S, Haug U, Brenner H.
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53.



(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)